Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19.
Ontology highlight
ABSTRACT: The potential emergence of SARS-CoV-2 variants capable of escaping vaccine-generated immune responses poses a looming threat to vaccination efforts and will likely prolong the duration of the COVID-19 pandemic. Additionally, the prevalence of beta coronaviruses circulating in animals and the precedent they have set in jumping into human populations indicates that they pose a continuous threat for future pandemics. Currently, only one therapeutic is approved by the U.S. Food and Drug Administration (FDA) for use in treating COVID-19, remdesivir, although other therapies are authorized for emergency use due to this pandemic being a public health emergency. In this review, twenty-four different treatments are discussed regarding their use against COVID-19 and any potential future coronavirus-
SUBMITTER: Malek RJ
PROVIDER: S-EPMC8486678 | biostudies-literature | 2021 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA